Disease · MONDO_0000831

thrombotic disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. thrombotic disease. Diseases, record MONDO_0000831. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000831

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: thrombotic disease; Open Targets
Open Targets ID: MONDO_0000831; Open Targets
Other names: Clots, blood, Thromboses, blood Clots, blood clot, clot, blood, thrombosis, thrombotic disorder, thrombus; Open Targets
Disease Ontology: DOID:0060903; Disease Ontology
MeSH: D013927; MeSH
NCI Thesaurus: C26891; NCI Thesaurus
Highest stage of its drugs: Approval, for 18 of its 85 drugs, from DailyMed, PMDA and TTD; Open Targets

Drugs85

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RIVAROXABAN	CHEMBL198362	Small molecule	Approval	PMDA	10	9	9	Drugs and targets
WARFARIN	CHEMBL1464	Small molecule	Approval	ClinicalTrials.gov, at phase 4	9	8	6	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Approval	PMDA	6	4	4	Drugs and targets
TICAGRELOR	CHEMBL398435	Small molecule	Approval	TTD	5	4	4	Drugs and targets
CLOPIDOGREL	CHEMBL1771	Small molecule	Approval	TTD	4	3	3	Drugs and targets
APIXABAN	CHEMBL231779	Small molecule	Approval	TTD	3	2	2	Drugs and targets
BIVALIRUDIN	CHEMBL5314348	Protein	Approval	DailyMed	3	1	1	Drugs and targets
ARGATROBAN	CHEMBL1166	Small molecule	Approval	DailyMed and TTD	2	0	0	Drugs and targets
BICIROMAB	CHEMBL2108410	Antibody	Approval	TTD	2	0	0	Drugs and targets
ACENOCOUMAROL	CHEMBL397420	Small molecule	Approval	TTD	1	0	0	Drugs and targets

1 to 10 of 85

See all 85 drugs

Targets44

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
F10	Coagulation factor X	6	Coagulation factor X inhibitor	Approval	https://conductscience.org/library/genes/2159	Drugs and targets
SERPINC1	Antithrombin-III	6	Antithrombin-III activator	Phase 3	https://conductscience.org/library/genes/462	Drugs and targets
F2	Prothrombin	5	Thrombin inhibitor	Approval	https://conductscience.org/library/genes/2147	Drugs and targets
VKORC1	Vitamin K epoxide reductase complex subunit 1	5	Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor	Approval	https://conductscience.org/library/genes/79001	Drugs and targets
P2RY12	P2Y purinoceptor 12	4	Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor; Purinergic receptor P2Y12 negative allosteric modulator	Approval	https://conductscience.org/library/genes/64805	Drugs and targets
ATP4A	Potassium-transporting ATPase	2	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	2	Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/496	Drugs and targets
F11	Coagulation factor XI	2	Coagulation factor XI inhibitor; Coagulation factor XI negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2160	Drugs and targets
AR	Androgen receptor	1	Androgen Receptor degrader	Phase 2	https://conductscience.org/library/genes/367	Drugs and targets
BACE1	Beta-secretase 1	1	Beta-secretase 1 inhibitor	Phase 1	https://conductscience.org/library/genes/23621	Drugs and targets

1 to 10 of 44

See all 44 targets

Trials37

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00401414	Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information	Not applicable	344	2013-08-30	Pulmonary Embolism, Deep Vein Thrombosis, Atrial Fibrillation	WARFARIN	Its record names the disease	ClinicalTrials.gov
NCT00814177	Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients	Phase 2	160	2009-11-25	Atrial Fibrillation, Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction	WARFARIN	Its record names the disease	ClinicalTrials.gov
NCT00674297	Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients	Phase 2	41	2018-05-01	Antiphospholipid Syndrome	FLUVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT02540668	A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants	Phase 1	15	2019-03-25	Healthy	LANABECESTAT, WARFARIN	Its record names the disease	ClinicalTrials.gov
NCT02223260	Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age	Phase 2	8	2016-09-20	Venous Thromboembolism	DABIGATRAN ETEXILATE	Its record names the disease	ClinicalTrials.gov
NCT00133731	The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention	Phase 2	947		Angioplasty, Transluminal, Percutaneous Coronary	OTAMIXABAN	Its record names the disease	ClinicalTrials.gov
NCT00143715	Oral Vitamin K for Warfarin Associated Coagulopathy	Phase 3	690		Coagulation, Bleeding, Thrombosis	PHYTONADIONE	Its record names the disease	ClinicalTrials.gov
NCT00839163	Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)	Phase 2	613		Venous Thrombosis, Deep Vein Thrombosis	RIVAROXABAN	Its record names the disease	ClinicalTrials.gov
NCT04165629	Platelet Reactivity in PAD Undergoing Percutaneous Angioplasty		450		Peripheral Artery Disease, Critical Limb Ischemia, Claudication, Intermittent	ASPIRIN, CLOPIDOGREL	Its record names the disease	ClinicalTrials.gov
NCT01267305	The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery	Not applicable	362		Lung Neoplasms, Esophageal Neoplasms, Venous Thromboembolism	FONDAPARINUX, NADROPARIN CALCIUM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 37

See all 37 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
No Change vs Change: Number of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks	48 of 80	45 of 80	160	NCT00814177	Trial comparisons
No Change vs Change: serious adverse events	0 of 80	0 of 80	160	NCT00814177	Trial comparisons

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39002729	RESULT	1	PubMed
19640572	RESULT	1	PubMed
39900192	DERIVED	1	PubMed
39773831	DERIVED	1	PubMed
33779986	DERIVED	1	PubMed
32355836	DERIVED	1	PubMed
29481926	DERIVED	1	PubMed
29269513	DERIVED	1	PubMed
22449204	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000831

GET https://conductscience.org/api/diseases/v1/MONDO_0000831/drugs?page=2

API reference For AI assistants